首页> 外文OA文献 >Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines
【2h】

Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines

机译:使用通用指南改进15个实验室之间的DNa流式细胞仪,DNa倍性和s期重现性以分析乳腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Lack of generalized guidelines for DNA flow cytometric analysis (FCM) may be the main reason for its limited use in the clinical management of breast cancer. Methods: After an initial interlaboratory reproducibility study (Round 1), we concluded that it was the evaluation of the DNA histograms rather than the technical performance of the analysis that was the main reason for discordant results between laboratories. Guidelines for the interpretation of DNA histograms were therefore drawn up. We present here data from a new reproducibility study (Round 11) using these guidelines. Results: For 10 laboratories also participating in Round 1, use of the guidelines increased the concordance in DNA ploidy status from 89% to 100% for the 46 samples used in both rounds. The concordance rate for SPF also increased; mean r(s)-value increased from 0.81 to 0.88, and mean kappa value (lower two-thirds versus upper third versus not reported) increased from 0.55 to 0.71. Five new laboratories, participating only in Round II, also agreed with the 10 original laboratories regarding DNA ploidy status. With the inclusion of all 15 laboratories, we obtained a mean r(s)-value of 0.81 and a mean kappa value of 0.72 for SPF. Conclusions: Generalized guidelines for DNA FCM increase interlaboratory agreement, which is highly important in clinical routines and in multicenter studies. Furthermore, inexperienced FCM laboratories using generalized guidelines can produce and interpret DNA FCM data equally as well as experienced laboratories. Cytometry Part A 56A:1-7, 2003. (C) 2003 Wiley-Liss, Inc.
机译:背景:缺乏通用的DNA流式细胞术分析(FCM)指南可能是其在乳腺癌临床管理中使用受限的主要原因。方法:经过初步的实验室间可重复性研究(第1轮),我们得出结论,DNA直方图的评估而不是分析的技术性能是导致实验室之间结果不一致的主要原因。因此,制定了DNA直方图解释指南。我们在此使用这些指南提供来自新的再现性研究(第11轮)的数据。结果:对于也参加第1轮的10个实验室,使用指南将两轮使用的46个样品的DNA倍性状态一致性从89%提高到100%。 SPF的符合率也有所提高;平均r(s)值从0.81增加到0.88,平均kappa值(下三分之二与上三分之二对未报告)从0.55增加到0.71。仅参加第二轮研究的五个新实验室也就DNA倍体状态与10个原始实验室达成了一致。包括所有15个实验室在内,我们得出SPF的平均r(s)值为0.81,平均kappa值为0.72。结论:DNA FCM通用指南增加了实验室间的一致性,这在临床常规和多中心研究中非常重要。此外,没有经验的FCM实验室可以使用通用的准则,与经验丰富的实验室一样,产生和解释DNA FCM数据。细胞计数法A 56A:1-7,2003.(C)2003 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号